Cellid Co., Ltd.

Quick facts

Phase 3 pipeline

• AdCLD-CoV19-1 OMI · Immunology / Infectious Disease
  AdCLD-CoV19-1 OMI is an adenoviral vector-based vaccine designed to elicit immune responses against Omicron variant SARS-CoV-2 antigens.

Phase 1 pipeline

• AdCLD-CoV19
• BVAC-B
• BVAC-C

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cellid Co., Ltd. portfolio CI brief
• Cellid Co., Ltd. pipeline updates RSS